Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 12/11/2025 | $660.00 | Neutral → Buy | Citigroup | |
| 12/9/2025 | $685.00 | Buy | Goldman | |
| 12/8/2025 | $750.00 | Sector Weight → Overweight | KeyBanc Capital Markets | |
| 12/2/2025 | $670.00 | Overweight | Morgan Stanley | |
| 12/1/2025 | $670.00 | Hold → Buy | HSBC Securities | |
| 9/11/2025 | $550.00 | Equal Weight → Overweight | Barclays | |
| 8/19/2025 | Outperform | William Blair | ||
| 7/24/2025 | $510.00 | Buy → Hold | HSBC Securities |
8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
424B5 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
FWP - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - Seer, Inc. (0001726445) (Issuer)
4 - Seer, Inc. (0001726445) (Issuer)
Citigroup upgraded Thermo Fisher from Neutral to Buy and set a new price target of $660.00
Goldman initiated coverage of Thermo Fisher with a rating of Buy and set a new price target of $685.00
KeyBanc Capital Markets upgraded Thermo Fisher from Sector Weight to Overweight and set a new price target of $750.00
Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher") announced today that it has priced an offering of $3.8 billion aggregate principal amount (the "Offering") of the following notes: $1.0 billion aggregate principal amount of its 4.215% senior notes due 2031 (the "2031 notes") at the issue price of 100.000% of their principal amount; $750 million aggregate principal amount of its 4.550% senior notes due 2033 (the "2033 notes") at the issue price of 99.783% of their principal amount; $1.3 billion aggregate principal amount of its 4.902% senior notes due 2036 (the "2036 notes") at the issue price of 100.000% of their principal amount; and $750 million aggregate principal am
REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the fourth quarter and full year 2025 on Thursday, February 26, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to th
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Fourth quarter revenue grew 7% to $12.21 billion. Fourth quarter GAAP diluted earnings per share (EPS) grew 9% to $5.21. Fourth quarter adjusted EPS grew 8% to $6.57. Full year revenue grew 4% to $44.56 billion. Full year GAAP diluted earnings per share (EPS) grew 7% to $17.74. Full year adjusted EPS grew 5% to $22.87. Delivered another year of excellent operational performance and share gain reflecting our active management of the company, the
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire
Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as
REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. "We are excited to welcome Isaac to our board," said Omid Farokhzad, Chair and CEO of Seer. "Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven track record of guiding companies through transformative growth will be invaluable as we continue to execute on key milestones and accelerate the impact of our platform." "I'm looking forward to work
REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the fourth quarter and full year 2025 on Thursday, February 26, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to th
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Fourth quarter revenue grew 7% to $12.21 billion. Fourth quarter GAAP diluted earnings per share (EPS) grew 9% to $5.21. Fourth quarter adjusted EPS grew 8% to $6.57. Full year revenue grew 4% to $44.56 billion. Full year GAAP diluted earnings per share (EPS) grew 7% to $17.74. Full year adjusted EPS grew 5% to $22.87. Delivered another year of excellent operational performance and share gain reflecting our active management of the company, the
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2025 before the market opens on Thursday, January 29, 2026, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. The call will be webcast live on the "Investors" section of our website, www.thermofisher.com. You can access the conference call by dialing (833) 470-1428 within the U.S. or +1 (646) 844-6383 outside the U.S. The access code is 054943. The earnings press release and related information can also be fo
SC 13G/A - Seer, Inc. (0001726445) (Subject)
SC 13G/A - Seer, Inc. (0001726445) (Subject)
SC 13G/A - Seer, Inc. (0001726445) (Subject)